Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction.

[1]  H. Rakowski.  Determining Hypertrophic Cardiomyopathy Mortality: Gaining Wisdom From Knowledge. , 2019, JAMA cardiology.

[2]  S. Ommen,et al.  Survival Following Myectomy for Obstructive Hypertrophic Cardiomyopathy-What Causes Late Mortality? , 2019, The Annals of thoracic surgery.

[3]  M. Link,et al.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.

[4]  B. Maron,et al.  Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy. , 2019, Journal of cardiac failure.

[5]  L. Lopes,et al.  Genetic characterization and genotype-phenotype associations in a large cohort of patients with hypertrophic cardiomyopathy - An ancillary study of the Portuguese registry of hypertrophic cardiomyopathy. , 2019, International journal of cardiology.

[6]  B. Maron,et al.  Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. , 2019, JACC. Clinical electrophysiology.

[7]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[8]  C. Autore,et al.  Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[9]  B. Maron,et al.  Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[10]  B. Maron,et al.  Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy. , 2018, JACC. Heart failure.

[11]  Sainan Cheng,et al.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase , 2018, The International Journal of Cardiovascular Imaging.

[12]  M. Maurer,et al.  Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2018, Circulation. Heart failure.

[13]  I. Olivotto,et al.  Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. , 2018, Journal of the American College of Cardiology.

[14]  M. Link,et al.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy , 2017, Circulation.

[15]  Deepak L. Bhatt,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[16]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[17]  P. Elliott,et al.  Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy , 2016, Heart.

[18]  C. Rapezzi,et al.  Histological and Histometric Characterization of Myocardial Fibrosis in End-Stage Hypertrophic Cardiomyopathy: A Clinical-Pathological Study of 30 Explanted Hearts , 2016, Circulation. Heart failure.

[19]  B. Maron,et al.  How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. , 2016, JAMA cardiology.

[20]  B. Maron,et al.  What Do Patients With Hypertrophic Cardiomyopathy Die from? , 2016, The American journal of cardiology.

[21]  F. Girolami,et al.  Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy , 2015, Circulation. Heart failure.

[22]  M. Link,et al.  Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.

[23]  F. Rutten,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[24]  W. Roberts,et al.  Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant , 2014, Circulation. Heart failure.

[25]  C. Autore,et al.  Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. , 2014, The American journal of cardiology.

[26]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[27]  K. Hayashi,et al.  Impact of Systolic Dysfunction in Genotyped Hypertrophic Cardiomyopathy , 2013, Clinical cardiology.

[28]  L. Jordaens,et al.  Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy: Systematic Review and Meta-Analysis , 2012, Circulation. Heart failure.

[29]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[30]  B. Bornstein,et al.  Genetic basis of end‐stage hypertrophic cardiomyopathy , 2011, European journal of heart failure.

[31]  R. Favaloro,et al.  Comparison of prevalence, clinical course, and pathological findings of left ventricular systolic impairment versus normal systolic function in patients with hypertrophic cardiomyopathy. , 2011, The American journal of cardiology.

[32]  N. Hagiwara,et al.  Risk of sudden death in end-stage hypertrophic cardiomyopathy. , 2011, Journal of cardiac failure.

[33]  S. Kushwaha,et al.  Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2011, Circulation. Heart failure.

[34]  M. Maron,et al.  Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[35]  W. Manning,et al.  Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[36]  A. Angelini,et al.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy , 2010, European heart journal.

[37]  G. Boriani,et al.  Heart transplantation in hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[38]  G. Giannakoulas,et al.  Prevalence of systolic impairment in an unselected regional population with hypertrophic cardiomyopathy. , 2006, American Journal of Cardiology.

[39]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[40]  G. Boriani,et al.  Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. , 2005, Journal of the American College of Cardiology.

[41]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[42]  W. Mckenna,et al.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.

[43]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[44]  M. Carrier,et al.  Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeutic option. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[46]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .

[47]  B. Gersh,et al.  Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.